Crohn’s disease

by Sarah C.P. Williams, Broad Institute of MIT and Harvard edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Graphical abstract. Credit: Cell (2026). DOI: 10.1016/j.cell.2025.12.013 An estimated 3 million Americans have an inflammatory bowel disease (IBD) such as Crohn’s disease or ulcerative colitis. But a lucky few individuals are far less likely

by University of Oxford edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Fibroblast states that support fistula tract epithelialization. Credit: Nature (2025). DOI: 10.1038/s41586-025-09744-y. Scientists at the University of Oxford, have identified how rare populations of abnormal cells drive the formation and persistence of fistulas—painful, tunnel-like tracts that develop in around 30% of people with Crohn’s disease. The

by University of California – San Diego edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes Electron micrographs show how macrophages expressing girdin neutralize pathogens by fusing phagosomes (P) with the cell’s lysosomes (L) to form phagolysosomes (PL), compartments where pathogens and cellular debris are broken down (left). This process is crucial for maintaining cellular homeostasis. In

by Osaka University edited by Gaby Clark, reviewed by Robert Egan Overexpression of RUNX2 and BHLHE40 induces TRM, which remain in the intestine, and are involved in inflammation in Crohn’s disease. Credit: Mitsuru Arase and The University of Osaka A research group has revealed that transcription factors RUNX2 and BHLHE40 play crucial roles in inducing T cells involved

by The Mount Sinai Hospital edited by Sadie Harley, reviewed by Andrew Zinin High magnification micrograph of Crohn’s disease. Biopsy of esophagus. H&E stain. Credit: Nephron/Wikipedia In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is

by Cedars-Sinai Medical Center edited by Lisa Lock, reviewed by Robert Egan   High magnification micrograph of Crohn’s disease. Biopsy of esophagus. H&E stain. Credit: Nephron/Wikipedia Cedars-Sinai investigators have developed an investigational therapy that brought a significant number of patients with moderate to severe Crohn’s disease into remission, according to a new study published in The Lancet Gastroenterology & Hepatology. The